.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average follow-up of 11 months, people with metastatic intestinal growths that acquired biomarker-matched therapies based upon distributing tumor DNA profiling presented a more significant scientific benefit than those acquiring unmatched therapy.